Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 10 04:00PM ET
21.65
Dollar change
-1.18
Percentage change
-5.17
%
Index- P/E- EPS (ttm)- Insider Own53.99% Shs Outstand33.38M Perf Week9.51%
Market Cap723.49M Forward P/E- EPS next Y- Insider Trans89.08% Shs Float15.35M Perf Month-5.50%
Income- PEG- EPS next Q-0.57 Inst Own42.19% Short Float2.25% Perf Quarter-
Sales- P/S- EPS this Y- Inst Trans- Short Ratio2.27 Perf Half Y-
Book/sh8.13 P/B2.66 EPS next Y- ROA- Short Interest0.35M Perf Year-
Cash/sh8.29 P/C2.61 EPS next 5Y- ROE- 52W Range15.31 - 27.50 Perf YTD-8.46%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-21.27% Beta-
Dividend TTM- Quick Ratio25.75 Sales past 5Y0.00% Gross Margin- 52W Low41.41% ATR (14)2.50
Dividend Ex-Date- Current Ratio25.75 EPS Y/Y TTM- Oper. Margin- RSI (14)54.37 Volatility14.95% 13.06%
Employees- Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price37.25
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-138.42% Payout- Rel Volume2.48 Prev Close22.83
Sales Surprise- EPS Surprise-2.33% Sales Q/Q- EarningsNov 07 BMO Avg Volume151.98K Price21.65
SMA2011.38% SMA500.02% SMA200-1.07% Trades Volume377,229 Change-5.17%
Date Action Analyst Rating Change Price Target Change
Oct-08-24Initiated Stifel Buy $40
Oct-08-24Initiated JP Morgan Overweight $30
Oct-08-24Initiated Jefferies Buy $35
Oct-08-24Initiated Guggenheim Buy $44
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mathers Edward TDirectorSep 16 '24Buy16.00500,0008,000,0003,614,486Sep 17 08:28 PM
BASKETT FOREST10% OwnerSep 16 '24Buy16.00500,0008,000,0003,614,486Sep 17 08:26 PM
Behbahani Ali10% OwnerSep 16 '24Buy16.00500,0008,000,0003,614,486Sep 17 08:24 PM
Chang Carmen10% OwnerSep 16 '24Buy16.00500,0008,000,0003,614,486Sep 17 08:23 PM
Florence Anthony A. Jr.10% OwnerSep 16 '24Buy16.00500,0008,000,0003,614,486Sep 17 08:21 PM
Makhzoumi Mohamad10% OwnerSep 16 '24Buy16.00500,0008,000,0003,614,486Sep 17 08:20 PM
Walker Paul Edward10% OwnerSep 16 '24Buy16.00500,0008,000,0003,614,486Sep 17 08:18 PM
Yang Rick10% OwnerSep 16 '24Buy16.00500,0008,000,0003,614,486Sep 17 08:17 PM
SANDELL SCOTT D10% OwnerSep 16 '24Buy16.00500,0008,000,0003,614,486Sep 17 08:14 PM
ORBIMED ADVISORS LLCDirectorSep 16 '24Buy16.00750,00012,000,0003,158,428Sep 17 08:13 PM
New Enterprise Associates 17, 10% OwnerSep 16 '24Buy16.00500,0008,000,0003,614,486Sep 17 08:12 PM
Frazier Life Sciences X, L.P.10% OwnerSep 16 '24Buy16.00625,00010,000,0004,552,774Sep 17 08:11 PM
Heron Patrick JDirectorSep 16 '24Buy16.00625,00010,000,0004,552,774Sep 17 08:09 PM
Aynechi TibaDirectorSep 16 '24Buy16.00750,00012,000,0002,136,335Sep 17 08:05 PM
GORDON CARL LDirectorSep 16 '24Buy16.00750,00012,000,0003,158,428Sep 17 08:05 PM